2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15121R
    L-Theanine (Standard) 3081-61-6 99.98%
    L-Theanine (Standard) is the analytical standard of L-Theanine. This product is intended for research and analytical applications. L-Theanine (L-Glutamic Acid γ-ethyl amide) is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective, anticancer and anti-oxidative activities. L-Theanine can pass through the blood–brain barrier and is orally active.
    L-Theanine (Standard)
  • HY-15121S
    L-Theanine-d5 1217451-85-8 99.9%
    L-Theanine-d5 is the deuterium labeled L-Theanine. L-Theanine (L-Glutamic Acid γ-ethyl amide）is a non-protein amino acid contained in green tea leaves, which blocks the binding of L-glutamic acid to glutamate receptors in the brain, and with neuroprotective and anti-oxidative activities. L-Theanine causes anti-stress effects via the inhibition of cortical neuron excitation by oral intake.
    L-Theanine-d5
  • HY-152026
    NADPH oxidase-IN-1 2762405-17-2 99.69%
    NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy.
    NADPH oxidase-IN-1
  • HY-153019
    NUCC-0000323 663212-78-0 99.86%
    NUCC-0000323 is a potent superoxide dismutase 1 (SOD1) inhibitor. NUCC-0000323 inhibits SOD1 expression. NUCC-0000323 can be used in research of amyotrophic lateral sclerosis (ALS).
    NUCC-0000323
  • HY-153559
    Lp-PLA2-IN-13 2756855-62-4 99.87%
    Lp-PLA2-IN-13 (compound 15) is a potent Lp-PLA2 inhibitor. Lp-PLA2-IN-13 has the potential for the research of neurodegenerative related diseases.
    Lp-PLA2-IN-13
  • HY-153584
    MRK-898 461450-30-6 99.48%
    MRK-898 is an orally active GABA(A) receptor modulator. MRK-898 binds to α1, α2, α3 or α5 subunit of GABA(A) receptor with Ki values of 1.2 nM, 1.0 nM, 0.73 nM, and 0.50 nM, respectively. However, α1-containing GABA(A) receptors are identified as the "sedative" and α2- and/or α3-containing receptors as the "anxiolytic" subtype(s).
    MRK-898
  • HY-154851
    GSK-3 inhibitor 3 2227279-84-5 99.10%
    GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC50s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research.
    GSK-3 inhibitor 3
  • HY-15568A
    A-317491 sodium salt hydrate 99.88%
    A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X3 and P2X2/3 receptors, with Kis of 22, 22, 9, and 92 nM for hP2X3, rP2X3, hP2X2/3, and rP2X2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X3 and P2X2/3 receptor-mediated calcium flux.
    A-317491 sodium salt hydrate
  • HY-155830
    Morcamilast 2231329-25-0 98.92%
    Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC50s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of TNF-α, IL-12/23p40, IL-23, and IL-17A in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases.
    Morcamilast
  • HY-156131
    Loperamide 53179-11-6 99.85%
    Loperamide (ADL 2-1294) is selective and orally active μ opioid receptor agonist with Ki valuess of 3, 48 and 1156 nM against μ, δ and κ opioid receptor, respectively. Loperamide produces antinociception and antihyperalgesia. Loperamide exhibits peripheral selectivity, enhancing fluid, electrolyte, and glucose absorption, reversing PGE2 (HY-101952)- and Cholera toxin (HY-P1446)-induced intestinal secretion, and reducing intestinal motility. Loperamide can be used for the researches of inflammatory pain and protracted diarrhoea.
    Loperamide
  • HY-156429
    MK-1468 2769107-89-1 99.69%
    MK-1468 is an orally active, selective, and BBB-permeable LRRK2 inhibitor. MK-1468 can be used for the research of Parkinson's disease.
    MK-1468
  • HY-158243
    Fallypride precursor 166173-74-6 98.92%
    Fallypride precursor (Compound 15) is a drug intermediate that can be used for synthesis of Fallypride (HY-135497).
    Fallypride precursor
  • HY-160831
    PQQ-trimethylester 74447-88-4
    PQQ-trimethylester (PQQ-TME) is a synthetic compound that is a trimethylester derivative of pyrroloquinoline quinone (PQQ). PQQ-trimethylester has twice the blood-brain barrier permeability of PQQ (HY-100196) in vitro. In addition, PQQ-trimethylester shows strong inhibitory activity against α-synuclein, amyloid β1-42 (Aβ1-42) and prion protein fibrillation. PQQ-trimethylester can be used in the study of neurodegenerative diseases.
    PQQ-trimethylester
  • HY-161104
    Kv2.1-IN-1 2252448-93-2 98.64%
    Kv2.1-IN-1 is an orally active and blood-brain barrier penetrant Kv2.1 inhibitor with an IC50 of 0.07 μM. Kv2.1-IN-1 exhibits a selectivity >130 fold over other K+, Na+, and Ca2+ ion channels. Kv2.1-IN-1 decreases the apoptosis of HEK293 cells induced by H2O2. Kv2.1-IN-1 produces significant neuroprotection efficacy in middle cerebral artery occlusion (MCAO) rat. Kv2.1-IN-1 can be used for the study of ischemic stroke.
    Kv2.1-IN-1
  • HY-162596
    NRL-1049 1973494-16-4 99.96%
    NRL-1049 (BA-1049 (free base)) is an orally available and selective ROCK2 inhibitor with IC50 values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations.
    NRL-1049
  • HY-163565
    BIIB129 2770960-52-4 99.54%
    BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells. BIIB129 can be used in multiple sclerosis (MS) research.
    BIIB129
  • HY-16677A
    Mofegiline hydrochloride 120635-25-8 99.57%
    Mofegiline hydrochloride (MDL72974A) is an orally active and selective enzyme-activated irreversible inhibitor of MAO-B, with marked selectivity on the MAO-B over MAO-A with IC50s of 3.6 nM (MAO-B) and 680 nM (MAO-A), respectively. Mofegiline hydrochloride is also an inhibitor of semicarbazide-sensitive amine oxidase (SSAO).
    Mofegiline hydrochloride
  • HY-16713A
    (S)-(-)-5-Fluorowillardiine (hydrochloride) 1321546-70-6 99.03%
    (S)-(-)-5-Fluorowillardiine ((5S)-Fluorowillardiine; (S)-5-Fluorowillardiine) hydrochloride is a potent, highly selective non-NMDA ionotropic glutamate receptor (iGluR, AMPA/Kainate receptor) agonist. (S)-(-)-5-Fluorowillardiine hydrochloride activates high-affinity AMPA-preferring receptors (EC50 = 0.70 μM) and low-affinity kainate-preferring receptors (EC50 = 170 μM), thereby inducing biphasic dose-dependent neurotoxicity/excitotoxicity. (S)-(-)-5-Fluorowillardiine hydrochloride is applicable to research related to schizophrenia, temporal lobe epilepsy, and bipolar disorder.
    (S)-(-)-5-Fluorowillardiine (hydrochloride)
  • HY-169109
    DAPK1-IN-1 1429522-04-2 99.80%
    DAPK1-IN-1 (compound 10) is a death-associated protein kinase 1 (DAPK1) inhibitor with a Kd value of 0.63 μM. DAPK1-IN-1 can be used in Alzheimer’s disease research.
    DAPK1-IN-1
  • HY-171179
    BD-Oligo 1357578-02-9 98.18%
    BD-Oligo is an oligomer-specific fluorescent chemical probe. BD-Oligo preferentially identifies Aβ oligomer assemblies over monomers or fibrils by using diversity-directed fluorescent library (DOFL) screening and computational techniques. BD-Oligo exhibits dynamic oligomer monitoring capabilities during Aβ peptide fibril formation as Aβ is induced to form oligomers and ultimately fibrils over time. BD-Oligo also exhibits blood-brain barrier permeability with the ability to stain Aβ oligomers in vivo.
    BD-Oligo
Cat. No. Product Name / Synonyms Application Reactivity